ZA200706208B - Bacterial glycolipid activation of CD1d-restricted NKT cells - Google Patents
Bacterial glycolipid activation of CD1d-restricted NKT cells Download PDFInfo
- Publication number
- ZA200706208B ZA200706208B ZA200706208A ZA200706208A ZA200706208B ZA 200706208 B ZA200706208 B ZA 200706208B ZA 200706208 A ZA200706208 A ZA 200706208A ZA 200706208 A ZA200706208 A ZA 200706208A ZA 200706208 B ZA200706208 B ZA 200706208B
- Authority
- ZA
- South Africa
- Prior art keywords
- cell
- nkt
- cells
- cd1d
- response
- Prior art date
Links
- 210000000581 natural killer T-cell Anatomy 0.000 title claims description 105
- 229930186217 Glycolipid Natural products 0.000 title claims description 50
- 230000001580 bacterial effect Effects 0.000 title claims description 50
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims description 27
- 230000004913 activation Effects 0.000 title description 17
- 238000000034 method Methods 0.000 claims description 36
- 210000004443 dendritic cell Anatomy 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 21
- 230000028993 immune response Effects 0.000 claims description 19
- 241000605314 Ehrlichia Species 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 14
- 230000003213 activating effect Effects 0.000 claims description 9
- 241000606651 Rickettsiales Species 0.000 claims description 8
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims description 7
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 230000005784 autoimmunity Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims description 4
- 241001495399 Ehrlichia muris Species 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 241000605317 Anaplasmataceae Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 27
- 241000736131 Sphingomonas Species 0.000 description 23
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 241000607142 Salmonella Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 101100094860 Mus musculus Slc22a6 gene Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 210000004989 spleen cell Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241001135756 Alphaproteobacteria Species 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- JMENXJYBCQFIRK-KRJDXUSZSA-N N-hexacosanoylisoglobotriaosyl ceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 JMENXJYBCQFIRK-KRJDXUSZSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000736107 Novosphingobium capsulatum Species 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 101150071246 Hexb gene Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 4
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229940035024 thioglycerol Drugs 0.000 description 4
- UFDULEKOJAEIRI-UHFFFAOYSA-N (2-acetyloxy-3-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I)=C1OC(C)=O UFDULEKOJAEIRI-UHFFFAOYSA-N 0.000 description 3
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000589157 Rhizobiales Species 0.000 description 3
- 241001185305 Sphingomonadales Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- -1 phosphatidylinosital Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052814 silicon oxide Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241000249497 Brucellaceae Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000131972 Sphingomonadaceae Species 0.000 description 2
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 1
- 241000606662 Bartonellaceae Species 0.000 description 1
- 241000131971 Bradyrhizobiaceae Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001185306 Caulobacterales Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000219774 Griffonia Species 0.000 description 1
- 241000168520 Holosporaceae Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 241000191917 Hyphomicrobiaceae Species 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001430266 Methylocystaceae Species 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000982667 Phyllobacteriaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001633102 Rhizobiaceae Species 0.000 description 1
- 241001185307 Rhodobacterales Species 0.000 description 1
- 241000253387 Rhodobiaceae Species 0.000 description 1
- 241000131970 Rhodospirillaceae Species 0.000 description 1
- 241001185316 Rhodospirillales Species 0.000 description 1
- 241000606683 Rickettsiaceae Species 0.000 description 1
- 241001135759 Sphingomonas sp. Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- UNSKAUSCLTVFGO-FSIIMWSLSA-N methyl (2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-FSIIMWSLSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200706208B true ZA200706208B (en) | 2008-04-30 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200706208A ZA200706208B (en) | 2005-01-28 | 2007-07-26 | Bacterial glycolipid activation of CD1d-restricted NKT cells |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (enExample) |
| EP (1) | EP1848813B1 (enExample) |
| JP (1) | JP5053101B2 (enExample) |
| AU (1) | AU2006211485B2 (enExample) |
| BR (1) | BRPI0607299A2 (enExample) |
| CA (1) | CA2593715C (enExample) |
| DK (1) | DK1848813T3 (enExample) |
| ES (1) | ES2423005T3 (enExample) |
| PL (1) | PL1848813T3 (enExample) |
| PT (1) | PT1848813E (enExample) |
| WO (1) | WO2006083671A2 (enExample) |
| ZA (1) | ZA200706208B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| PT2056842E (pt) * | 2006-04-07 | 2013-01-24 | Univ Chicago | Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais |
| JP5564672B2 (ja) * | 2006-06-30 | 2014-07-30 | ザ スクリプス リサーチ インスティテュート | アジュバント及びその使用方法 |
| CA2683681A1 (en) * | 2007-04-13 | 2008-10-23 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
| US8916164B2 (en) * | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| AU2013202865B2 (en) * | 2007-11-07 | 2015-03-19 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2058011A1 (en) * | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| EP2231145B1 (en) * | 2007-12-05 | 2014-09-17 | Wittycell | Use of glycosylceramides for enhancing the immune response to antigens |
| WO2010040710A1 (en) | 2008-10-08 | 2010-04-15 | Wittycell | Vaccine composition for use against influenza |
| HUE038234T2 (hu) | 2009-02-25 | 2018-10-29 | Softkemo Pharma Corp | Bendamusztin és ciklopoliszacharid kompozíciók |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| JP6548579B2 (ja) * | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| JP2023522979A (ja) * | 2020-04-23 | 2023-06-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｉＮＫＴ細胞の活性化による老化細胞の排除 |
| JP2023553743A (ja) * | 2020-12-18 | 2023-12-25 | ロレアル | スフィンゴモナス属の細菌の抽出物 |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| IL305579A (en) | 2021-03-01 | 2023-10-01 | Deciduous Therapeutics Inc | Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| JP3717512B2 (ja) | 1992-10-22 | 2005-11-16 | 麒麟麦酒株式会社 | 新規スフィンゴ糖脂質およびその使用 |
| US5780441A (en) | 1993-04-15 | 1998-07-14 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipid compounds and therapeutic uses thereof |
| EP0698031A4 (en) | 1993-05-14 | 1997-07-09 | Cytel Corp | SIALYL LE x ANALOGUES AS INHIBITORS OF CELLULAR ADHESION |
| JP3495740B2 (ja) | 1997-04-10 | 2004-02-09 | 麒麟麦酒株式会社 | α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤 |
| JP2001515868A (ja) * | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Ｃｄ１制限免疫応答のための合成抗原 |
| US20030153514A1 (en) | 2000-04-28 | 2003-08-14 | Akikuni Yagita | Remedies for cancer |
| WO2001094949A2 (en) * | 2000-06-05 | 2001-12-13 | The Brigham And Women's Hospital, Inc. | Soluble cd1 compositions and uses thereof |
| US20020164331A1 (en) * | 2000-06-19 | 2002-11-07 | Exley Mark A. | Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations |
| AU2001268564A1 (en) * | 2000-06-22 | 2002-01-02 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| KR100549866B1 (ko) * | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| US20040266726A1 (en) | 2001-11-06 | 2004-12-30 | Akikuni Yagita | Anticancer compositions |
| US7273852B2 (en) * | 2002-06-13 | 2007-09-25 | The Research Foundation Of The City University Of New York | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| ES2344740T3 (es) | 2004-09-03 | 2010-09-06 | The University Of Chicago | Metodos para activar celulas nkt. |
| PT2056842E (pt) | 2006-04-07 | 2013-01-24 | Univ Chicago | Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais |
| JP5564672B2 (ja) | 2006-06-30 | 2014-07-30 | ザ スクリプス リサーチ インスティテュート | アジュバント及びその使用方法 |
-
2006
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es active Active
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Not-in-force
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1848813A4 (en) | 2008-07-09 |
| EP1848813B1 (en) | 2013-04-10 |
| CA2593715C (en) | 2015-05-05 |
| EP1848813A2 (en) | 2007-10-31 |
| PL1848813T3 (pl) | 2013-09-30 |
| WO2006083671B1 (en) | 2007-04-12 |
| JP5053101B2 (ja) | 2012-10-17 |
| DK1848813T3 (da) | 2013-07-15 |
| US9295722B2 (en) | 2016-03-29 |
| WO2006083671A3 (en) | 2007-02-22 |
| US20080279894A1 (en) | 2008-11-13 |
| PT1848813E (pt) | 2013-07-15 |
| BRPI0607299A2 (pt) | 2009-08-25 |
| WO2006083671A2 (en) | 2006-08-10 |
| JP2008528608A (ja) | 2008-07-31 |
| AU2006211485B2 (en) | 2011-04-14 |
| ES2423005T3 (es) | 2013-09-17 |
| CA2593715A1 (en) | 2006-08-10 |
| AU2006211485A1 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200706208B (en) | Bacterial glycolipid activation of CD1d-restricted NKT cells | |
| Lee et al. | Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells | |
| Brigl et al. | How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens | |
| Fusakio et al. | C5a regulates NKT and NK cell functions in sepsis | |
| US20220257745A1 (en) | Compositions comprising of bacterial strains | |
| Jeong et al. | Invariant natural killer T cells in lung diseases | |
| Kikuchi et al. | Dendritic cells pulsed with live and dead Legionella pneumophila elicit distinct immune responses | |
| Haque et al. | Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 mice by activation of NK cells and NK-T cells | |
| Takagi et al. | Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues | |
| Florence et al. | CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences | |
| Harada et al. | Highly expressed dectin-1 on bone marrow-derived dendritic cells regulates the sensitivity to β-glucan in DBA/2 mice | |
| US20090117089A1 (en) | Glycolipids and analogues thereof as antigens for nk t cells | |
| Seya et al. | Two receptor theory in innate immune activation: studies on the receptors for bacillus Culmet Guillen-cell wall skeleton | |
| US7928088B2 (en) | Th1 cell differentiation accelerator | |
| Kamuthachad et al. | Invariant natural killer T (iNKT) cells response in human melioidosis | |
| Gillard et al. | Functional programming of innate immune cells in response to bordetella pertussis infection and vaccination | |
| McPherson | Evaluation of the Mode of Action of Sulfated Lactosyl Archaeol Adjuvant: Interaction with L-selectin and Impact of Administration Route | |
| KR101209416B1 (ko) | 헤파린 결합 헤마글루틴（ｈｂｈａ）을 아쥬반트로 이용한 수지상 세포 암 치료제 | |
| Ohtsubo et al. | Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2, 3, 6'-trimycolate | |
| Alwethaynani | Exploiting the potential of iNKT cells to improve vaccination | |
| KR20250121023A (ko) | 강글리오사이드 NGcGM3의 합성 변형체 및 암 치료를 위한 그것의 용도 | |
| Danielli | CALHM6: Function in the innate immune system and role in infectious diseases | |
| Mierzejewska et al. | De-O-acylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity | |
| KR101290230B1 (ko) | 결핵균의 Ｒｖ0652 단백질을 아쥬반트로 이용한 수지상 세포 암 치료제 | |
| Lu | Acyloxyacyl Hydrolase: Studies on Its Regulation and Function in Mus Musculus |